Omlyclo set to become commercially available in Europe
The drug Omlyclo, the first and only omalizumab biosimilar in Europe, will be commercially available in the European market, biopharmaceutical company Celltrion has announced.
Omlyclo, a drug used to treat chronic spontaneous urticaria (CSU), allergic asthma and chronic rhinosinusitis with nasal polyps, will be available in Norway before subsequent rollouts in other European countries.
The announcement follows results from the global Phase III clinical trial of Omlyclo (CT-P39), presented at the 2025 European Academy of Dermatology and Venereology (EADV) Congress last week.
The global Phase III clinical trial involved 619 patients with CSU, following them up to week 40. Patients were randomised to receive 300mg or 150mg of Omlyclo, or reference product, every four weeks. Starting from week 12, patients who received Omlyclo were continued on the same treatment and patients who initially received 300mg of the reference product were re-randomised in a 1:1 ratio to either switch to Omlyclo or to continue receiving the reference product.
From week 24 until week 40, patients were observed without dosing. The results demonstrated that Omlyclo had comparable efficacy and safety to reference product during both treatment and off dose periods.
“Immuno-dermatology diseases such as CSU significantly impact a patient’s quality of life, affecting various aspects including mental and emotional well-being, social life, daily activities, and even financial stability,” said Professor Martin Metz, Deputy Director of the Institute of Allergology, Charité-Universitätsmedizin Berlin, Germany.
“Availability of an omalizumab biosimilar in the EU is both timely and significant, offering a much-needed option for patients and healthcare providers. The clinical trial of Omlyclo clearly met the safety and efficacy endpoints, thereby offering a tangible promise for all eligible patients.”
“At this year’s EADV Congress, Celltrion reinforced dermatologists’ confidence in Omlyclo, the first and only omalizumab biosimilar in Europe, by presenting robust clinical evidence supporting its biosimilarity and assuring physicians that switching from the original product to Omlyclo is safe,” said Taehun Ha, Senior Vice President and Head of Europe at Celltrion.
“As a biosimilar-focused company, we remain committed to building long-term trust with healthcare professionals and strengthening our presence in the European market.”
Bruno Quinney, Content Team, DDW
